whatshot

ESALY   $61.65  -1.34% Market Closed

Eisai Co Ltd
show_chart Advanced Chart of ESALY
Last Events:

2023-03-29 Trend pattern changed from расходящийся клин с наклоном вверх to симметричный треугольник.

2023-03-29 Signal in Stochastic changed from bearish weakening to bearish. The stochastic indicator is in the oversold territory and it falls. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: entry into the oversold zone.

2023-03-29 Signal in MACD changed from bearish to bearish recovery. Oscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: main and signal line crossing.

2023-03-29 Signal in EMA100 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-03-29 Signal in EMA50 changed from bullish reversal to bearish reversal. 2023-01-24 the price crossed down the moving average line and formed a short-term downside trend.

2023-03-29 Trend Power changed from strong to almost flat.

2023-03-29 Trend changed from turning up to down and flat.

2023-03-29 Trend pattern changed from симметричный треугольник to расходящийся клин с наклоном вверх.

Current temperature: 2.89
ST: 0, Cor:

50-50 Year Forecast
Low with 50% probability: 50.45
Target: 80.00
High with 50% probability: 77.93
Analyst Recommendations:
Number of estimates 1
Target Price Mean 80.00
Mean unverified/preliminary 80.00 / 80.00
Target Price Low / High 80.00 / 80.00
Median / STD DEV 80.00 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total - - Sell
rsi Sell Sell Sell
macd - Sell Sell
stoch Buy - -
ma20 Sell - -
ma50 Sell - -
ma100 - - -
Candlestick PatternJan. 5, 2023 Bullish Belt Hold - is a candlestick that has a long white body and small shadows. It opens on the low of the day. It occurs in a downtrend. Considered to be a bullish reversal pattern.
ISIN US2825793092
ceo Mr. Haruo Naito
Website https://www.eisai.co.jp
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.